News

DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule -- Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome --

March 8, 2017

DalCor’s Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule -- Dalcetrapib Studied in Genetically Distinct Patients with Acute Coronary Syndrome --

Read more

First Canadian Electrophysiology Laboratory Equipped with Robotic Magnetic Navigation System Dedicated to Patients with Congenital Heart Diseases

February 15, 2017

The Montreal Heart Institute is proud to announce the opening of the very first electrophysiology laboratory (EP Lab) equipped with robotic and magnetic navigation and dedicated to congenital heart diseases in Canada. Congenital heart diseases are cardiac malformations that affect approximately 1% of all Canadians.

Read more